Sleep duration and ischemic heart disease and all-cause mortality: Prospective cohort study on effects of tranquilizers/hypnotics and perceived stress

by Garde AH, Hansen ÅM, Holtermann A, Gyntelberg F, Suadicani P

Sleep duration and psychological stress during work and leisure time interact as risk factors for ischemic heart disease (IHD) mortality. This may explain previously observed inconsistencies in the literature on sleep duration and stress as risk indicators for IHD mortality, and suggests that the negative effects of stress during work and leisure time could be reduced with sufficient sleep.

Affiliation: National Research Centre for the Working Environment, Lersø Parkallé 105, DK-2100 Copenhagen, Denmark. ahg@nrcwe.dk

Refers to the following texts of the Journal: 2006;32(6):493-501
2006;32(6):482-492

The following articles refer to this text: 2013;39(6):531-533;
2014;40(6):569-581

Key terms: all-cause mortality; Copenhagen Male Study; hypnotic; ischemic heart disease; male; prospective cohort study; sleep; sleep duration; stress; tranquilizer

This article in PubMed: www.ncbi.nlm.nih.gov/pubmed/23804297
Sleep duration and ischemic heart disease and all-cause mortality: Prospective cohort study on effects of tranquilizers/hypnotics and perceived stress

by Anne Helene Garde, PhD,1 Åse Marie Hansen, PhD,1, 2 Andreas Holtermann, PhD,1 Finn Gyntelberg MD,3 Poul Suadicani, DDS 3

Garde AH, Hansen ÅM, Holtermann A, Gyntelberg F, Suadicani P. Sleep duration and ischemic heart disease and all-cause mortality: Prospective cohort study on effects of tranquilizers/hypnotics and perceived stress. Scand J Work Environ Health. 2013;39(6):550–558. doi:10.5271/sjweh.3372

Objectives This prospective study aimed to examine if sleep duration is a risk indicator for ischemic heart disease (IHD) and all-cause mortality, and how perceived stress during work and leisure time and use of tranquilizers/hypnotics modifies the association.

Method A 30-year follow-up study was carried out in the Copenhagen Male Study comprising 5249 men (40–59 years old). Confounders included lifestyle factors (smoking, alcohol, and leisure-time physical activity), clinical and health-related factors (body mass index, blood pressure, diabetes, hypertension, and physical fitness) and social class. Men with a history of cardiovascular disease at baseline were excluded.

Results During follow-up, 587 men (11.9%) died from IHD and 2663 (53.9%) due to all-cause mortality. There were 276 short (<6 hours), 3837 medium (6–7 hours), and 828 long (≥8 hours) sleepers. Men who slept <6 hours had an increased risk of IHD mortality but not all-cause mortality, when referencing medium sleepers. Perceived psychological pressure during work and leisure was not a significant effect modifier for the association between sleep duration and IHD mortality. In contrast, among men using tranquilizers/hypnotics (rarely or regularly), short sleepers had a two-to-three fold increased risk of IHD mortality compared to medium sleepers. Among those never using tranquilizers/hypnotics, no association was observed between sleep duration and IHD mortality.

Conclusion Short sleep duration is a risk factor for IHD mortality among middle-aged and elderly men, particularly those using tranquilizers/hypnotics on a regular or even a rare basis, but not among men not using tranquilizers/hypnotics.

Key terms Copenhagen Male Study; male.
factors may be risk indicators for IHD mortality (20). Over the past years, numerous studies have evaluated the association between CVD and psychological stress, eg, work-related psychosocial factors [reviewed in (20, 21)] and leisure-time factors such as major life events (22).

Thus associations between sleep duration or psychological stress during work or leisure time on the one hand and IHD/all-cause mortality on the other have been studied extensively over the past years. Yet, the results are inconsistent. Several theories [eg, the psychophysiological effort-recovery theories (23, 24), the theory of allostasis (25, 26), and the cognitive activation theory of stress (27)] imply that it is a combination of short sleep duration and stress rather than sleep duration and stress independently that is important for the development of disease and mortality. However, to our knowledge, this has not been scientifically investigated. As a result, using a large cohort of middle-aged men in the Copenhagen Male Study with a 30-year follow-up, we prospectively examined the following research questions: (i) Is sleep duration independently associated with IHD mortality and all-cause mortality? (ii) Does psychological stress during work and leisure time modify the association between sleep duration and IHD mortality? (iii) Do use of tranquilizers/hypnotics modify the association between sleep duration and IHD mortality?

Methods

Study design and population

The present study is a prospective cohort study with 30 years follow-up based on the Copenhagen Male Study, which was established in 1970–1971. All men aged 40–59 years at 14 companies in Copenhagen, covering the railway, public road construction, military, post, telephone, customs, national bank, and the medical industry, were invited to participate. In total, 5249 men, 87% of potential participants, signed up (28, 29).

The examination consisted of a questionnaire, a short interview, and a clinical examination including measurements of height, weight, blood pressure, and physical (cardiorespiratory) fitness. Indirect measurement of cardiorespiratory fitness (VO₂Max) was performed using a bicycle ergometer. Thirty-five men with orthopedic problems unable to perform the bicycle test were excluded from the study.

Information about sleep duration, perceived psychological pressure during work and leisure time, lifestyle, and general health, including history of myocardial infarction, angina pectoris, and intermittent claudication was obtained from the questionnaire (30). One of the authors clarified the information given in the questionnaire in the ensuing interview with each subject.

Sleep duration

Participants reported their daily number of hours of sleep in categories: <6, 6–7, 8–9, and >9 hours. The distribution of answers in these groups was: 5.6%, 77.7%, 16.3%, and 0.4%, respectively, among men eligible for the study. Due to the small number of men reporting >9 hours sleep, the latter two groups were pooled for the analyses. Accordingly, respondents were classified as short (<6 hours), medium (6–7 hours) and long (8–9 and >9) hours sleepers.

Potential markers of psychological stress

Psychological stress was assessed through three questions: (i) “Are you under psychological pressure when performing your work?” Answer options were: “rarely” and “regularly”. (ii) “Are you under psychological pressure in your leisure time?” Answer options were: “rarely” and “regularly”. (iii) “Do you take tranquilizers or sleep medicine?” Answer options were: “rarely”, “regularly” and “never”.

Lifestyle factors

Smoking. The men reported if they smoked currently, previously, or had never smoked.

Alcohol. Participants also reported their daily average alcohol consumption as the number of alcoholic beverages consumed per day in categories: 0, 1–2, 3–5, 6–10, and >10 drinks.

Leisure-time physical activity. This was assessed by the question: “Which description most precisely covers your pattern of physical activity in leisure time?”. The response categories were: (i) “You are mainly sedentary eg, you read, watch television, and go to the pictures. In general you spend most of your leisure time performing sedentary tasks.” (ii) “You go for a walk, use your bicycle a little or perform activity for ≥4 hours/week, eg, light gardening, leisure-time building activity, table tennis and bowling.” (iii) “You are an active athlete, run, play tennis or badminton for ≥3 hours/week. If you frequently perform heavy gardening, you also belong to this group.” (iv) “You take part in competitive sports, swim, play European football, handball or run long distances regularly ie, several times/week.” In the statistical analyses, group 1 is referred to as “low” and group 2 as “moderate”; since only 0.4% belonged to group 4, groups 3 and 4 were pooled and referred to as “high”.

Scand J Work Environ Health 2013, vol 39, no 6 551
Clinical and health-related factors

**Body mass index (BMI).** Based on height and weight measurements, BMI was calculated as body weight in kilograms by height in meters squared (kg/m²).

**Blood pressure.** Measurements of blood pressure were carried out with the subject seated and after ≥5 minutes rest. A 12-cm wide, 26-cm-long cuff was firmly and evenly applied to the subject’s right upper arm with the lower edge of the cuff placed 2 cm antecubitally. Diastolic blood pressure was recorded at the point where the Korotkoff sounds disappeared (phase 5).

**Diabetes and hypertension treatment.** The participants were asked if they received treatment due to diabetes and/or hypertension from their physician or elsewhere. Answer options were “yes” and “no”.

**Physical fitness.** Physical fitness was assessed according to Åstrand’s bicycle ergometer test (31). The method used has previously been described in detail (28).

**Social class**
The men were divided into five social classes according to a system originally elaborated by Svalastoga, later adjusted by Hansen (32, 33). This classification system is based on education level and job position in terms of number of subordinates.

Eligibility
In addition to the 35 men unable to carry out the bicycle test, men with a history of myocardial infarction (N=74), angina pectoris (N=165) or intermittent claudication (N=105) were excluded from the prospective study. In total, this latter group comprised 274 men leaving 4943 men for the incidence study. With respect to all variables included, missing values ranged from 0–2.7%.

End-points
Information on death diagnoses within the period 1970–1971 to end of 2001 was obtained from official national registers and may therefore be considered complete. The ICD mortality diagnoses encompassed the International Classification of Diseases, revision 8, (ICD-8): 410–14 and (from 1994) ICD-10: I20–I25.

Statistical analysis
Basic statistical analyses, including Chi-squared analysis (likelihood ratio), analysis of variance, trend test (Kendall’s tau B), and regression analyses, were performed by use of SPSS version 18.0 (IBM Corporation, Armonk, NY, USA). Relative risks were estimated by \( \exp(\beta) \), where \( \beta \) is the hazard coefficient for the variable of interest in a Cox’s proportional hazards regression model with the maximum likelihood ratio method. Assumptions regarding the use of Cox’s proportional hazards were met by inspection of the log minus log function at the covariate mean. Confounders included lifestyle factors (smoking, alcohol, and leisure-time physical activity), clinical and health-related factors (BMI, blood pressure, diabetes and hypertension, and physical fitness) and social class because other studies have found them to be related to sleep duration and cardiovascular risk. Cox proportional hazards regression analysis with IHD mortality as outcome was used to obtain a statistical expression for the interdependency of sleep duration and perceived stress (research question 2) and frequency of use of tranquilizers/hypnotics (research question 3). In addition to main effects of the two variables, age, lifestyle factors, and other potential confounders, we included a multiplicative interaction term between sleep duration (3 levels) and the variables depicting either perceived stress (no pressure, pressure at either work or leisure, pressure at both work and leisure) or use of tranquilizers/hypnotics (never, rarely, regularly). For all analyses, a two-sided probability value of P<0.05 was a priori taken as significant.

Results
In the eligible study population of male employees without history of myocardial infarction, angina pectoris, or intermittent claudication, 587 died (11.9%) from IHD during the period 1970–1971 to 2001. During the same period, 2663 (53.9%) died in total.

Table 1 illustrates lifestyle and other characteristics according to self-reported daily sleep duration among men without history of myocardial infarction, angina pectoris, or intermittent claudication. Long sleep duration was associated with slightly lower VO₂Max, less psychological pressure during leisure time, and more seldom use of tranquilizers/hypnotics. Male workers sleeping 6–7 hours were slightly younger, were more physically active during leisure time, perceived less psychological pressure during work hours, and drank less alcohol. They also had lower diastolic blood pressure and lower BMI than male workers, who slept <6 or ≥8 hours. No significant associations were observed between levels of sleep duration and social class, smoking status, diabetes, systolic blood pressure, or hypertension.

Analysis of correlations between use of tranquilizers/hypnotics and sleep duration showed that 19% of those not using tranquilizers/hypnotics reported exposure to
Table 1. Lifestyle and other characteristics in 1970–1971 according to self-assessed daily sleep duration among men without history of myocardial infarction, angina pectoris, or intermittent claudication. [% freq=frequency in percent; SD=standard deviation; VO\textsubscript{2}Max=maximal oxygen consumption; BP=blood pressure; BMI=body mass index.]

|                                      | Short <6 hours (N=276) | Medium 6–7 hours (N=3837) | Long ≥8 hours (N=828) | P-value * | P-value a |
|--------------------------------------|------------------------|---------------------------|-----------------------|-----------|-----------|
|                                      | % freq | Mean  | SD       | % freq | Mean  | SD       | % freq | Mean  | SD       |           |           |
| Age                                  |        |       |          |        |       |          |        |       |          |           |           |
| Low social class (IV/V)              | 61.2   | 49.3  | 5.7      | 53.5   | 48.8  | 5.3      | 48.8   | 5.3   | 0.79     | 0.009     | 0.07      |
| Leisure-time physical activity       |        |       |          |        |       |          |        |       |          |           |           |
| Low                                  | 24.6   | 76.4  | 7.1      | 17.6   | 70.5  | 7.5      | 70.5   | 7.5   | 0.09     | 0.009     | 0.07      |
| Medium                               | 34.7   | 64.9  | 7.3      | 71.3   | 82.7  | 7.3      | 82.7   | 7.3   | 0.07     | 0.009     | 0.07      |
| High                                 | 10.4   | 14.5  | 8.8      | 19.1   | 18.6  | 19.1     | 18.6   | 19.1  | 0.06     | 0.009     | 0.07      |
| Physical fitness                     |        |       |          |        |       |          |        |       |          |           |           |
| VO\textsubscript{2}Max               | 33.4   | 20.1  | 2.7      | 4.1    | 22.6  | 4.3      | 22.6   | 4.3   | 0.55     | 0.04      |           |
| Perceived psychological pressure     |        |       |          |        |       |          |        |       |          |           |           |
| during work hours                    |        |       |          |        |       |          |        |       |          |           |           |
| Rarely                               | 72.3   | 34.7  | 33.7     | 34.1   | 27.7  | 48.8     | 43.2   | 27.7  | 0.001    | 0.001     |           |
| Regularly                            | 27.7   | 76.4  | 71.8     | 70.5   | 22.6  | 19.1     | 19.1   | 22.6  | 0.001    | 0.001     |           |
| Perceived psychological pressure     |        |       |          |        |       |          |        |       |          |           |           |
| during leisure time                  |        |       |          |        |       |          |        |       |          |           |           |
| Rarely                               | 14.9   | 85.1  | 93.2     | 95.9   | 10.5  | 21.5     | 15.4   | 10.5  | 0.001    | 0.001     |           |
| Regularly                            | 22.6   | 19.1  | 8.8      | 10.4   | 15.4  | 17.6     | 4.6    | 15.4  | 0.001    | 0.001     |           |
| Clinical risk factors                |        |       |          |        |       |          |        |       |          |           |           |
| Diabetes                             | 1.8    | 0.6   | 0.6      | 1.0    | 1.9    | 1.5      | 0.75   | 0.75  | 0.48     |           |           |
| Systolic BP (mm Hg)                  |        |       |          |        |       |          |        |       |          |           |           |
| 135.5                                | 134.4  | 83.9  | 11.8     | 135.9  | 83.9  | 11.7     | 0.75   | 0.75  | 0.48     |           |           |
| 15.6                                | 11.8   | 11.7  | 11.7     | 8.8    | 11.7  | 8.8      | 0.75   | 0.75  | 0.48     |           |           |
| Diastolic BP (mm Hg)                 |        |       |          |        |       |          |        |       |          |           |           |
| 89.2                                | 92.7   | 82.7  | 11.7     | 83.9   | 83.9  | 11.7     | 0.75   | 0.75  | 0.48     |           |           |
| 12.3                                | 11.7   | 11.7  | 11.7     | 8.8    | 11.7  | 8.8      | 0.75   | 0.75  | 0.48     |           |           |
| Hypertension d                       | 2.2    | 2.2   | 1.5      | 1.9    | 2.2   | 1.5      | 1.9    | 2.2   | 0.75     | 0.48      |           |
| BMI (kg/m\textsuperscript{2})        |        |       |          |        |       |          |        |       |          |           |           |
| 25.6                                | 25.2   | 25.4  | 2.9      | 2.9    | 25.4  | 2.9      | 2.9    | 25.4  | 0.07     | 0.007     |           |

* P-values of trend test (Kendall’s tau B) or test for linearity in analysis of variance.
* a P-values of Chi-square test or test for deviation in analysis of variance.
* b Receives doctor’s treatment due to diabetes.
* c Receives doctor’s treatment due to hypertension.

Table 2. Number of hours sleep and risk of ischemic heart disease and all-cause mortality 1970–1971 to end of 2001. Different adjustment criteria are applied in Cox proportional hazards regression analyses with forced entry of variables. [HR=hazard ratios; 95% CI=95% confidence interval; BMI=body mass index; BP=blood pressure; VO\textsubscript{2}Max=maximal oxygen consumption.]

| Mortality and sleep duration (hours/day) | N     | % crude incidence | HR a | 95% CI | HR b | 95% CI | HR c | 95% CI | HR d | 95% CI |
|-----------------------------------------|-------|-------------------|------|--------|------|--------|------|--------|------|--------|
| Ischemic heart disease                  |       |                   |      |        |      |        |      |        |      |        |
| <6                                      | 276   | 17.8              | 1.64 | 1.22–2.21 | 1.56 | 1.15–2.12 | 1.55 | 1.15–2.10 | 1.46 | 1.07–2.00 |
| 6–7                                     | 3837  | 11.1              | 1.00 | ..     | 1.00 | ..     | 1.00 | ..     | 1.00 | ..     |
| ≥8                                      | 828   | 13.7              | 1.22 | 0.99–1.51 | 1.24 | 1.01–1.53 | 1.16 | 0.94–1.44 | 1.20 | 0.97–1.49 |
| All-cause mortality                     |       |                   |      |        |      |        |      |        |      |        |
| <6                                      | 276   | 61.7              | 1.21 | 1.03–1.41 | 1.10 | 0.93–1.29 | 1.17 | 0.99–1.37 | 1.06 | 0.90–1.25 |
| 6–7                                     | 3837  | 53.4              | 1.00 | ..     | 1.00 | ..     | 1.00 | ..     | 1.00 | ..     |
| ≥8                                      | 828   | 54.5              | 1.02 | 0.92–1.13 | 1.00 | 0.90–1.11 | 1.00 | 0.90–1.11 | 0.99 | 0.84–1.09 |

a Adjusted for age.
b Adjusted for age + alcohol use, smoking (current, never, previous), leisure-time physical activity.
c Adjusted for age + BMI, systolic BP, diastolic BP, diabetes (treatment for), hypertension (treatment of), physical fitness (VO\textsubscript{2}Max).
d Adjusted for age + BMI, systolic BP, diastolic BP, diabetes (treatment for), hypertension (treatment of), physical fitness (VO\textsubscript{2}Max), alcohol use, smoking (current, never, previous), leisure-time physical activity, and social class.
work stress; among rare and regular users of tranquilizers/hypnotics, 27% and 44%, respectively, reported exposure to work stress. Corresponding figures with respect to psychosocial stress during leisure time were 5%, 10%, and 25%.

In table 2, the results of Cox proportional hazard regression analysis for associations between sleep duration and IHD and all-cause mortality, respectively, are presented. Short sleep duration (<6 hours) was associated with the highest risk of IHD mortality expressed as hazard ratio (HR) and 95% confidence interval (95% CI) when using medium sleepers as the reference group even when adjusting for all confounders (HR 1.46, 95% CI 1.07–2.0). No significant associations were found between sleep duration and all-cause mortality.

Table 3 shows the results of the Cox proportional hazard regression analysis for associations between number of hours sleep and risk of IHD mortality within groups stratified according to self-assessed psychological pressure during work and leisure. Among men reporting no pressure, short sleepers had an increased risk when adjusting for age and lifestyle only. When adjusting further for clinical factors like BMI, blood pressure, and diabetes, and also use of tranquilizers/hypnotics and social class, the significance disappeared. Among men with perceived psychological pressure either at work or during leisure time, no significant associations were observed between sleep duration and IHD mortality. This was the case also among men reporting pressure at work as well as during leisure time when adjusting for age plus other factors. A tendency of a higher risk was seen among a small group of men (N=17) with long sleep duration when controlling for clinical factors only, an observation with little impact due to the small number in the analysis.

Table 4 shows the results of the regression analyses for the association between number of hours sleep and risk of IHD mortality according to the use of tranquilizers/hypnotics. Among men who reported never having used tranquilizers/hypnotics, no association was found between sleep duration and risk of IHD death. Among men using tranquilizers/hypnotics rarely, an increased risk of IHD death (HR 2.50, 95% CI 1.31–1.84) was observed for short sleepers, referencing medium sleepers when adjusting for all confounders in the analysis. This was the case also for short sleepers who were regular users of tranquilizers/hypnotics (HR 3.03, 95% CI 1.32–6.95) when controlling for all confounders. Among men with long sleep duration, when adjusting for all confounders, no significant associations were found between sleep duration and IHD mortality risk among neither rare nor regular users of tranquilizers/hypnotics.

Additional analysis

As described in the statistics section, we performed a final formal analysis testing the interaction of sleep duration and frequency of tranquilizer use as a risk factor for IHD mortality. The interaction was significant on the 0.05 level, whereas neither sleep duration nor tranquilizer use alone could uphold statistical significance as independent risk factors.

Table 3. Number of hours sleep and risk of ischemic heart disease mortality 1970–1971 to end of 2001 according to self-assessed psychological pressure during work and leisure. Different adjustment criteria are applied in Cox proportional hazards regression analyses with forced entry of variables. [HR=hazard ratios; 95% CI=95% confidence interval; BMI=body mass index; BP=blood pressure; V0,Max=maximal oxygen consumption]

| Pressure and sleep duration (hours/day) | N  | % crude incidence | HRa | 95% CI | HRb | 95% CI | HRc | 95% CI | HRd | 95% CI |
|-----------------------------------------|----|------------------|-----|--------|-----|--------|-----|--------|-----|--------|
| No pressure                             |    |                  |     |        |     |        |     |        |     |        |
| <6                                      | 182| 17.7             | 1.55| 1.07–2.22 | 1.47| 1.02–2.14 | 1.41| 0.97–2.04 | 1.32| 0.90–1.94 |
| 6–7                                     | 2899| 11.3            | 1.00| --     | 1.00| --     | 1.00| --     | 1.00| --     |
| ≥8                                      | 620| 14.7             | 1.26| 1.00–1.58 | 1.28| 1.01–1.61 | 1.18| 0.93–1.49 | 1.24| 0.98–1.97 |
| Pressure either at work or during leisure time <6 | 68  | 14.9             | 1.37| 0.71–2.65 | 1.50| 0.77–2.93 | 1.41| 0.70–2.83 | 1.53| 0.75–3.12 |
| 6–7                                     | 777| 10.8             | 1.00| --     | 1.00| --     | 1.00| --     | 1.00| --     |
| ≥8                                      | 182| 9.4              | 0.92| 0.55–1.55 | 0.93| 0.54–1.60 | 0.88| 0.52–1.50 | 0.94| 0.54–1.64 |
| Pressure at work and during leisure time <6 | 25  | 24.0             | 3.10| 1.16–8.28 | 2.52| 0.81–7.87 | 2.57| 0.87–7.57 | 2.71| 0.69–10.57 |
| 6–7                                     | 143| 9.2              | 1.00| --     | 1.00| --     | 1.00| --     | 1.00| --     |
| ≥8                                      | 17 | 23.5             | 3.32| 1.08–10.25 | 3.22| 0.93–11.21 | 3.75| 1.18–11.95 | 3.70| 0.96–14.29 |

a Adjusted for age.

b Adjusted for age + alcohol use, smoking (current, never, previous), leisure-time physical activity.

c Adjusted for age + BMI, systolic BP, diastolic BP, diabetes (treatment for), hypertension (treatment of), physical fitness (V0,Max).

d Adjusted for age + BMI, systolic BP, diastolic BP, diabetes (treatment for), hypertension (treatment of), physical fitness (V0,Max), alcohol use, smoking (current, never, previous), leisure time physical activity, use of tranquilizers/hypnotics, and social class.
Table 4. Number of hours sleep and risk of ischemic heart disease mortality 1970–1971 to end of 2001 according to use of tranquilizers/hypnotics: never, rarely, and regularly. Different adjustment criteria are applied in Cox proportional hazards regression analyses with forced entry of variables. [HR=hazard ratios; 95% CI=95% confidence interval; BMI=body mass index; BP=blood pressure; VO\textsubscript{Max}=maximal oxygen consumption]

| Use of tranquilizers / hypnotics and sleep duration (hours/day) | N  | % Crude incidence | HR \textsuperscript{a} | 95% CI | HR \textsuperscript{b} | 95% CI | HR \textsuperscript{c} | 95% CI | HR \textsuperscript{d} | 95% CI |
|---------------------------------------------------------------|----|------------------|----------------|--------|----------------|--------|----------------|--------|----------------|--------|
| Never                                                         |    |                  |                |        |                |        |                |        |                |        |
| <6                                                           | 187| 12.9             | 1.13           | 0.74–1.70 | 1.06           | 0.70–1.63 | 1.08           | 0.71–1.66 | 0.94           | 0.60–1.48 |
| 6–7                                                          | 2957| 11.0             | 1.00           | ..      | 1.00           | ..      | 1.00           | ..      | 1.00           | ..      |
| ≥8                                                           | 661| 13.1             | 1.15           | 0.91–1.46 | 1.16           | 0.91–1.47 | 1.09           | 0.86–1.38 | 1.14           | 0.89–1.45 |
| Rarely                                                        |    |                  |                |        |                |        |                |        |                |        |
| <6                                                           | 59 | 22.4             | 2.64           | 1.46–4.77 | 2.75           | 1.50–5.02 | 2.40           | 1.29–4.47 | 2.50           | 1.31–4.80 |
| 6–7                                                          | 676| 10.7             | 1.00           | ..      | 1.00           | ..      | 1.00           | ..      | 1.00           | ..      |
| ≥8                                                           | 127| 16.5             | 1.62           | 1.0–2.64 | 1.66           | 1.01–2.71 | 1.52           | 0.92–2.52 | 1.43           | 0.85–2.42 |
| Regularly                                                     |    |                  |                |        |                |        |                |        |                |        |
| <6                                                           | 29 | 41.4             | 3.19           | 1.61–6.32 | 2.34           | 1.12–4.90 | 2.94           | 1.45–5.95 | 3.03           | 1.32–6.95 |
| 6–7                                                          | 199| 13.6             | 1.00           | ..      | 1.00           | ..      | 1.00           | ..      | 1.00           | ..      |
| ≥8                                                           | 38 | 15.8             | 1.31           | 0.54–3.18 | 1.28           | 0.52–3.13 | 1.61           | 0.65–3.97 | 1.72           | 0.65–4.56 |

\textsuperscript{a} Adjusted for age.
\textsuperscript{b} Adjusted for age + alcohol use, smoking (current, never, previous), leisure time physical activity.
\textsuperscript{c} Adjusted for age + BMI, systolic BP, diastolic BP, diabetes (treatment for), hypertension (treatment of), physical fitness (VO\textsubscript{Max}).
\textsuperscript{d} Adjusted for age + BMI, systolic BP, diastolic BP, diabetes (treatment for), hypertension (treatment of), physical fitness (VO\textsubscript{Max}), alcohol use, smoking (current, never, previous), leisure time physical activity, perceived psychological pressure during leisure time and work, and social class.

Discussion

In this large prospective study, overall we found that men who slept <6 hours had an increased risk of IHD mortality, when referencing those sleeping medium length (ie, 6–8 hours). When controlling for age only, some excess risk for all-cause mortality was also found for short sleepers, but not when controlling for other potential confounders. We therefore focused on IHD mortality. Perceived psychological pressure during work and leisure time was not a significant effect modifier for the association between sleep duration and IHD mortality. In contrast, among men using tranquilizers/hypnotics, whether rarely or regularly, short sleepers had a two to three fold increased risk of IHD mortality, compared to medium sleepers. Among those never using tranquilizers/hypnotics, no association was observed between sleep duration and IHD mortality.

Large individual differences in sleep duration exist (34), and although disturbed or short sleep is a well-known symptom of stress (35), short sleep is not necessarily perceived as non-restorative (36). Users of hypnotics must be assumed to experience negative consequences of short sleep severe enough to seek medical care. Furthermore, a quite strong association between perceived stress and use of tranquilizers/hypnotics was observed in the present study. Together this may reflect that men using tranquilizers/hypnotics are more psychologically stressed and experience less restorative sleep than men exclusively reporting being stressed or sleeping a short number of hours. If this interpretation is valid, our findings suggest that short sleep duration (as a measure of non-restorative sleep) alone is a risk factor for IHD mortality, and the effect is increased when short sleep duration is combined with use of tranquilizers/hypnotics (as a potential measure of stress). This fits very well with psychophysiological effort–recovery theories (23, 24), the theory of allostasis (25, 26) and the cognitive activation theory of stress (27). The theories underline the combination of prolonged or repeated stress and insufficient recovery in the development of disease.

It should be noted that tranquilizers/hypnotics in themselves may have physiological side effects associated with an increased risk of IHD (37). Use of hypnotics alone has been found to be associated with an increased mortality risk in previous studies, even among infrequent users of these drugs (8, 38, 39). We are aware of only one study which has investigated the interaction effects of sleep duration and hypnotics as risk indicators for IHD mortality (14). In contrast to our findings, Suzuki et al (14) found no effects of short sleep duration on CVD mortality among Japanese elderly residents with insomnia or use of hypnotics. The use of tranquilizers and hypnotics could theoretically induce metabolic changes either directly or via lifestyle changes, in particular a reduced physical activity level increasing the risk of IHD mortality. However, this explanation seems unlikely since in our study no association was found between the use of tranquilizers/hypnotics and IHD mortality among men with medium or long sleep duration.

The potential mechanisms by which extreme sleep habits may affect IHD mortality are not clear. However,
short-term sleep deprivation has been associated with several adverse physiological changes, eg, reduced glucose tolerance, increased sympathetic nervous activity, and activation of pro-inflammation pathways in experimental studies (18, 19). In the present study, we observed associations between sleep duration and specific mortality in terms of IHD mortality, but not all-cause mortality after adjustment for potential confounders. That sleep duration is associated with certain causes of death, but not others, suggests that specific pathways exist between sleep duration and cardiovascular mortality. The identification of specific pathways implies that (changes in) sleep duration has specific pathophysiological effects, rather than just being a marker of poor health or a clustering of other risk factors.

Strengths and limitations

Basic methodological challenges confronting the researcher in an epidemiological observational study include temporality, good validity of the exposure and outcome, and a sufficient confounder control. The present study fulfills the first and the latter challenges, and also the quality of the outcome measure must be considered sufficient, since the Danish national registers have been shown to have a high validity (40, 41). The present study relies on self-reports of sleep duration rather than objective measures. However, answers to a questionnaire addressing habitual sleep may in fact be a more relevant measure in a prospective epidemiological study than an objective measurement (eg, actigraphy performed over a limited time period). Furthermore, self-assessed sleep duration proves its internal validity by showing its capacity to discriminate subjects with different lifestyles and other characteristics as well as mortality risk. Sleep duration was reported in a priori fixed categories, which made the assessment cruder than if reported as a continuous variable. Furthermore, the categories may not be optimal. As an example, those sleeping 6 hours, who may have somewhat increased risk, are included in the mid-range sleepers and thereby increase the risk in the reference group; those sleeping 8–9 hours are included with the long sleepers and thereby decrease the risk in this group. The consequence of the potential misclassification of medium and long sleep would be an attenuation of the risk associated with long sleep duration, and may thus, at least to some degree, explain the lack of association between long sleep duration and mortality in the present study. Also the question asked on use of tranquilizers and hypnotics did not allow us to pin-point the indication for which the medicine was given. Still, both drugs are markers of subjective psychological stress. When interpreting the results it should be remarked that the baseline of the present study was carried out in 1970–1971 and there have been some changes in the type of drugs used as tranquilizers/hypnotics, which could potentially affect the results. During the 1970s there was a decrease in the sale of barbiturates and sedative–hypnotics, while the sale of benzodiazepines increased (42). During the 1990s, benzodiazepines have to some degree been replaced by z-hypnotics (eg, zaleplon and zolpidem). Although there are differences in the chemical structures, they both act as benzodiazepine receptor agonists and therefore initiate similar pathways (43). The study population of the Copenhagen Male Study is urban Danish male workers between 40–59 years of age in 1970–1971. The findings of this study should therefore be tested by other researchers and in other cohorts eg, females, younger workers, self-employed or workers from other (eg, rural) communities and of other nationalities.

Concluding remarks

The results of the present study show that short sleep duration is a risk factor for IHD mortality only among middle-aged and elderly men, particularly those using tranquilizers/hypnotics on a regular or even a rare basis, but not among men not using tranquilizers/hypnotics. Although a strong association was observed between perceived stress and frequency of tranquilizer use, no clear interplay was found between sleep duration, self-assessed psychological stress, and risk of IHD mortality.

Competing interest statement

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical considerations statement

When the Copenhagen Male Study was initiated as a closed cohort study in 1970–1971, no ethics committee for medical research had been established in Denmark. However, in 1985–1986, when survivors from the first baseline were re-examined, the study was approved by the ethics committee for medical research in the county of Copenhagen, and all participants in the study gave informed consent to participate, as stated in many previous publications from the Copenhagen Male Study based on analyses using the 1985–1986 baseline.
Acknowledgment

The present study did not receive funding. Other studies related to the cohort have previously received grants from the King Christian X's Foundation, the Danish Medical Research Council, the Danish Heart Foundation and the Else & Mogens Wedell-Wedellsborg Foundation. All authors declare themselves independent of funders.

All authors had full access to all of the data (including statistical tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Amagai Y, Ishikawa S, Gotoh T, Doi Y, Kayaba K, Nakamura Y, et al. Sleep du-ration and mortality in Japan: the Jichi Medical School Cohort Study. J Epidemiol. 2004;14:124–8. http://dx.doi.org/10.2188/jea.14.124.

2. Lane TY, Lan TH, Wen CP, Lin YH, Chuang YL. Nighttime sleep, chinese after-noon nap, and mortality in the elderly. Sleep. 2007;30:1105–10.

3. Ferlie JE, Shipley MJ, Capuccio FP, Brunner E, Miller MA, Kumari M, et al. A prospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. Sleep. 2007;30:1659–66.

4. Ikehara S, Isó H, Date C, Kikuchi S, Watanabe Y, Wada Y, et al. Association of Sleep Duration with Mortality from Cardiovascular Disease and Other Causes for Japanese Men and Women: the JACC Study. Sleep. 2009;32:29–301.

5. Patel SR, Ayas NT, Malhotra MR, White DP, Schernhammer ES, Speizer FE, et al. A prospective study of sleep duration and mortality risk in women. Sleep. 2004;27:440–4.

6. Burazeri G, Gofin J, Kark JD. Over 8 hours of sleep--marker of increased mor-tality in Mediterranean population: follow-up population study. Croat Med J. 2003;44:193–8.

7. Heslop P, Smith GD, Metcalfe C, Macleod J, Hart C. Sleep duration and mortali-ty: The effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. Sleep Med. 2002;3:305–14. http://dx.doi.org/10.1016/S1389-9457(02)00016-3.

8. Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry. 2002;59:131–6. http://dx.doi.org/10.1001/archpsyc.59.2.131.

9. Kripke DF, Langer RD, Elliott JA, Klauber MR, Rex KM. Mortality related to acti-graphic long and short sleep. Sleep Med. 2011;12:28–33. http://dx.doi.org/10.1016/j.sleep.2010.04.016.

10. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Opler MG, et al. Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample. Sleep. 2008;31:1087–96.

11. Gallièchio L, Kalesan B. Sleep duration and mortality: a systematic review and meta-analysis. J Sleep Res. 2009;18:148–58. http://dx.doi.org/10.1111/j.1365-2869.2008.00732.x.

12. Capuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33:585–92.

13. Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration pre-dicts cardiovascular outcomes: a systematic review and meta-analysis of pro-spective studies. Eur Heart J. 2011;32:1484–92. http://dx.doi.org/10.1093/eurheartj/ehr007.

14. Suzuki E, Yorifuji T, Ueshima K, Takao S, Sugiyama M, Ohta T, et al. Sleep du-ration, sleep quality and cardiovascular disease mortality among the elderly: a population-based cohort study. Prev Med. 2009;49:135–41. http://dx.doi.org/10.1016/j.ypmed.2009.06.016.

15. Shankar A, Koh WP, Yuan JM, Lee HP, Yu MC. Sleep Duration and Coronary Heart Disease Mortality Among Chinese Adults in Singapore: A Population-based Cohort Study. Am J Epidemiol. 2008;168:1367–73. http://dx.doi.org/10.1093/aje/kwn281.

16. Wingard DL, Berkman LF. Mortality risk associated with sleeping patterns among adults. Sleep. 1983;6:102–7.

17. Kronholm E, Laatikainen T, Peltonen M, Sippola R, Partonen T. Self-reported sleep duration, all-cause mortality, cardiovascular mortality and morbidity in Finland. Sleep Med. 2011;12:215–21. http://dx.doi.org/10.1016/j.sleep.2010.07.021.

18. Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, et al. Ef-fect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascu-lar risk. J Am Coll Cardiol. 2004;43:678–83. http://dx.doi.org/10.1016/j.jacc.2003.07.050.

19. Spiegel K, Leproult R, van Cauter E. Impact of sleep debt on metabolic and en-docrine function. Lancet. 1999;354:1435–9. http://dx.doi.org/10.1016/S0140-6736(99)01376-8.

20. Eller NH, Netterstrom B, Gyntelberg F, Kristensen TS, Nielsen F, Steptoe A, et al. Work-related psychosocial factors and the development of ischemic heart disease: a systematic review. Cardiol Rev. 2009;17:83–97. http://dx.doi.org/10.1007/CRD.0b013e318198ce89.

21. Backe EM, Seidler A, Latza U, Rossnagel K, Schumann B. The role of psycho-social stress at work for the development of cardiovascular diseases: a system-atic review. Int Arch Occup Environ Health. 2012;85:67–79. http://dx.doi.org/10.1007/S00420-011-0643-6.

22. Andersen I, Diderichsen F, Kornerup H, Prescott E, Rod NH. Major life events and the risk of ischaemic heart disease: does accumulation increase the risk? Int J Epidemiol. 2011;40:904–10. http://dx.doi.org/10.1093/ije/dyr052.

23. Geurts SA, Sonnentag S. Recovery as an explanatory mechanism in the rela-tion between acute stress reactions and chronic health impairment. Scand J Work Environ Health. 2006;32:482–92. http://dx.doi.org/10.5271/sjweh.1053.
24. Meijman TF, Mulder G. Psychological aspects of workload. In: Drenth PJD, Thierry H, de Wolff CJ, editors. Handbook of work and organizational psychology. 2nd ed. Hove: Psychology Press; 1998. p. 5–33.

25. McEwen BS. Stress, Adaptation, and Disease: Allostasis And Allostatic Load. Ann N Y Acad Sci. 1998;33–44. http://dx.doi.org/10.1111/j.1749-6632.1998.tb09546.x.

26. Sterling P, Eyer J. Allostasis: A New Paradigm to Explain Arousal Pathology. In: Fisher S, Reason J, editors. Handbook of Life Stress, Cognition and Health. Chichester: John Wiley & Sons; 1988. p. 629–49.

27. Ursin H, Eriksen HR. The cognitive activation theory of stress. Psychoneuroendocrinology. 2004;29:567–92. http://dx.doi.org/10.1016/S0306-4530(03)00091-X.

28. Gyntelberg F. Original title [Physical fitness and coronary heart-disease male residents in Copenhagen aged 40-59]. Dan Med Bull 1973;20:1–4.

29. Gyntelberg F. Original title [One-year and 2-years incidence of myocardial-infarction in Copenhagen males aged 40-59]. Dan Med Bull 1975;22:81–4.

30. Hein HO, Suadicani P, Gyntelberg F. Ischaemic heart disease incidence by so-cial class and form of smoking: the Copenhagen Male Study–17 years’ follow-up. J Intern Med. 1992;231:477–83. http://dx.doi.org/10.1111/j.1365-2796.1992.tb00963.x.

31. Åstrand P-O, Rodahl K. Textbook of work physiology. Physiological bases of exercise. New York: McGraw-Hill Book Company; 1986.

32. Svalastoga K. Prestige, class and mobility. Copenhagen: Munksgaard; 1959.

33. Hansen EJ. Original title [Socialgrupper i Danmark]. Copenhagen: Socialforskningsinstituttet; 1984.

34. Knutson KL, Rathouz PJ, Yan LL, Liu K, Lauderdale DS. Intra-individual daily and yearly variability in actigraphically recorded sleep measures: the CARDIA study. Sleep. 2007;30:793–6.

35. Åkerstedt T. Psychosocial stress and impaired sleep. Scand J Work Environ Health. 2006;32:493–501. http://dx.doi.org/10.5271/sjweh.1054.

36. Ohayon MM. Prevalence and correlates of nonrestorative sleep complaints. Arch Intern Med. 2005;165:35–41. http://dx.doi.org/10.1001/archinte.165.1.35.

37. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2:e000850. http://dx.doi.org/10.1136/bmjopen-2012-000850.

38. Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish popula-tion. J Intern Med. 2002;251:207–16. http://dx.doi.org/10.1046/j.1365-2796.2002.00941.x.

39. Kripke DF, Langer RD, Kline LE. Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open. 2012;2:e000850. http://dx.doi.org/10.1136/bmjopen-2012-000850.

40. Madsen M, Balling H, Eriksen LS. Original title [The validity of the diagnosis of acute myo-cardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry]. Dan Med Bull. 1990;152:308–14.

41. Mosbech J, Jorgensen J, Madsen M, Rostgaard K, Thorberg K, Poulsen TD. Original title [The national patient registry. Evaluation of data quality]. Dan Med Bull. 1995;157:3741–5.

42. Joldal B, Halvorsen I. Sales statistics in the control of drug abuse in Norway. Bull Narc. 1982;34:57–68.

43. Mendelson WB. Hypnotic Medications: Mechanisms of action and pharmacologic effects. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 4 ed. Philadelphia: Elsevier Saunders; 2005. p. 444–51.

Received for publication: 4 December 2012